Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.44 |
| ▸ | PARP15 | Q460N3 | 3/20 | 0.44 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20554028 | 0.82 | PRKCZ (0.37) | CHRNB2CHRNA4 | |
| SCHEMBL188620 | 0.81 | CHRNB2 (0.58) | PARP10PARP15CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL12509137 | 0.77 | TLR4 (0.45) | PARP10PARP15CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL7419188 | 0.76 | CHRNB2 (0.68) | CHRNB2CHRNA4 | |
| SCHEMBL7414932 | 0.76 | CHRNB2 (0.68) | CHRNB2CHRNA4 | |
| SCHEMBL14941165 | 0.75 | CHRNB2 (0.59) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL12557244 | 0.75 | CHRNB2 (0.61) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL4569107 | 0.75 | TLR4 (0.52) | PARP10PARP15 | |
| SCHEMBL29960864 | 0.75 | ACHE (0.53) | — | |
| SCHEMBL28512442 | 0.75 | ACHE (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239756-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239756-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | ENPP2, SSB, PLPBP | PARP10 1234/4885PARP15 716/4885CDK2 4227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.